Shukra Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY24Mar 2024	FY23Mar 2023

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.93×	0.99×
	1.15×	1.26×
	23.3%	6.0%
	0.98×	0.78×
	1.35×	2.96×
	32.9%	17.3%
	44.7%	17.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SHUKRAPHAR₹75.06

Shukra Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SGRL SUNLOCMcap ₹60.5 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.99	0.93
Interest Burden (Pretax/EBIT) ×	1.26	1.15
EBIT Margin %	5.99	23.27
Asset Turnover ×	0.78	0.98
Financial Leverage (Assets/Equity) ×	2.96	1.35
ROE (5-step product, year-end total equity) %	17.31	32.90
ROE (owners' profit / average owners' equity) %	17.42	44.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.